Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Exclusive Story 3 Undervalued Names Too Cheap to IgnoreReported by Nathan Reiff. Date Posted: 3/7/2026. 
Key Points - Several established companies present potential value plays in early 2026 thanks to comparably low P/E ratios and strong fundamentals, despite broader market challenges.
- Merck's recent rally has not compromised its P/E ratio, which remains below the industry average, as the company navigates new ways to grow revenue amid its flagship Keytruda nearing patent expiration.
- Campbell's and US Foods offer contrasting cases: the former experiencing a sharp pullback and a high dividend yield, while the latter rallying amid adjusted EBITDA gains and the potential for further improvement.
- Special Report: Elon Musk's $1 Quadrillion AI IPO
Highly publicized growth trajectories of some of the biggest companies out there may make it seem like 2026 is not an ideal time for a value strategy. Still, several sizable firms are trading at attractive valuations and could offer share-price appreciation alongside fundamental growth. The companies below are potential value plays, with metrics that are historically low and/or competitive relative to peers or the broader market. They also offer added benefits such as compelling dividends or promising product developments. While value opportunities can be harder to find when many growth names have regained investor attention—and some apparent "value" stocks suffer deteriorating operations—well-established, stable names can still represent attractive value prospects. Even After Rally, Merck May Be Undervalued, With Careful Planning for Keytruda in the Works Elon did the seemingly impossible – far faster than anyone expected… And it's sent the tech industry into PANIC MODE. ChatGPT, Claude, Google Gemini, and DeepSeek could soon become obsolete. And three little-known firms could soar 10X or higher as a result. Get the details here. Although shares have climbed more than 28% in the last year, bringing its market capitalization to nearly $300 billion, biopharma giant Merck & Co. Inc. (NYSE: MRK) still trades at a price-to-earnings (P/E) ratio of 16.45—well below the medical industry average of roughly 27. Analysts expect continued growth: the company is projected to see earnings climb by nearly 10% in the coming year and is forecast to have about 5% additional upside in the near term. Driving Merck's momentum is its pembrolizumab cancer drug, Keytruda, which received European Commission approval for subcutaneous injection in late 2025 and reached about $8.4 billion in sales in Q4 2025, an increase of nearly 7% year over year. Keytruda also shows promise in ovarian cancer, potentially expanding its patient base as Merck prepares for patent expiry in 2028. Merck's pipeline is broadening as well: the company recently announced phase 3 trial results for clesrovimab-cfor (Enflonsia), a treatment for RSV in young children. At the same time, Merck is reorganizing its human health operations—splitting the business into two units—to more easily expand non-cancer drug sales ahead of Keytruda's patent loss. A Difficult External Situation Pressures Campbell's, But Strong Dividend and Value Remain Factors Campbell's (NASDAQ: CPB) shares have declined about 37% over the last year as the food-and-beverage staple faced pressure from tariffs and inflation. In Q1 fiscal 2026, which ended Nov. 2, 2025, the company reported modest year-over-year declines in organic net sales and consumption, with adjusted earnings per share (EPS) down about 13% over the same period. The company has not yet realized notable margin improvement after initiating cost-saving measures. The near term likely remains challenging for the iconic food brand, and fiscal-year guidance is overall weak. That said, improving supply-chain operations and strong brand loyalty—especially for premium offerings—should provide some protection. Changes in tariff policies could also ease the pressure on margins. Importantly for income-focused investors, Campbell's remains a compelling dividend play, with a yield of 5.9%, though its payout ratio exceeds 80%. Its P/E ratio of 13.5 is the lowest in roughly four years, factors that may persuade some investors the stock is worth the risk despite Wall Street caution. A Recent US Foods Rally May Continue as Bottom-Line Growth Remains in Place Foodservice distribution leader US Foods (NYSE: USFD) has followed a very different path from Campbell's—in the last year, shares have risen about 33%. Its P/E ratio currently stands at 31.6. On fundamentals, US Foods is making important strides: the company reported improving profitability in the latest quarter and full-year adjusted EBITDA gains of 11% year over year. Better inventory management and cost-of-goods improvements are helping the firm gain traction. With a $4 billion capital deployment plan, US Foods is positioned to sustain revenue growth momentum and continue expanding adjusted EBITDA. Analysts rate USFD a Moderate Buy based on 11 Buys and 2 Holds, implying roughly 15% upside potential.
| 
